Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 19,123	$ 24,779
Short-term investments – available for sale	273,513	276,741
Prepaid clinical trial and preclinical study costs	343	335
Prepaid expenses and other current assets	665	278
Total current assets	293,644	302,133
Right-of-use assets	730
Deferred public offering and other financing costs	90	150
Deposits	29	29
Total assets	294,493	302,312
Current liabilities:
Accounts payable	1,870	959
Other accrued liabilities	3,468	3,591
Lease liability, current	288
Total current liabilities	5,626	4,550
Deferred rent		12
Lease liability, net of current portion	513
Total long-term liabilities	513	12
Total liabilities	6,139	4,562
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at June 30, 2019 and December 31, 2018; no shares issued and outstanding at June 30, 2019 and December 31, 2018
Common stock, $0.00001 par value: 300,000,000 shares authorized at June 30, 2019 and December 31, 2018; 72,173,489 and 71,742,043 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	1	1
Additional paid-in capital	403,630	401,090
Accumulated deficit	(115,516)	(102,918)
Accumulated other comprehensive income (loss)	239	(423)
Total stockholders’ equity	288,354	297,750
Total liabilities and stockholders’ equity	$ 294,493	$ 302,312